ストックスクリーナーアプリを入手
5.56
2.77%
0.15
アフターアワーズ：
5.69
0.13
+2.34%
前日終値:
$5.41
開ける：
$5.54
24時間の取引高:
16,004
Relative Volume:
0.38
時価総額：
$62.19M
収益：
$3.50M
当期純損益:
$-43.07M
株価収益率:
-0.8614
EPS:
-6.4543
ネットキャッシュフロー:
$-47.84M
1週間 パフォーマンス:
-4.55%
1か月 パフォーマンス:
-17.26%
6か月 パフォーマンス:
-28.53%
1年 パフォーマンス:
+0.00%
1日の値動き範囲:
$5.53
$5.75
1週間の範囲:
$5.35
$6.01
52週間の値動き範囲:
$5.35
$17.96
Imagenebio Inc Stock (IMA) Company Profile
Compare IMA vs VRTX, REGN, ALNY, ARGX, INSM
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
IMA
Imagenebio Inc
|
5.56 | 60.51M | 3.50M | -43.07M | -47.84M | -6.4543 |
VRTX
Vertex Pharmaceuticals Inc
|
454.97 | 113.96B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
749.47 | 78.41B | 14.34B | 4.50B | 3.77B | 41.56 |
ALNY
Alnylam Pharmaceuticals Inc
|
328.70 | 40.85B | 3.71B | 313.75M | 465.38M | 2.2571 |
ARGX
Argen X Se Adr
|
697.05 | 42.05B | 4.16B | 1.29B | 734.26M | 19.58 |
INSM
Insmed Inc
|
148.31 | 29.99B | 606.42M | -1.28B | -997.58M | -6.403 |
Imagenebio Inc Stock (IMA) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-11-25 | 再開されました | Wedbush | Underperform |
| 2025-10-24 | 開始されました | Leerink Partners | Outperform |
Imagenebio Inc (IMA) 最新ニュース
IMA,CVRX Volatility & Greeks - Finviz
IMA,CVRX Dividends - Finviz
ImageneBio (IMA) CEO receives 128,100 options and 85,400 RSUs - Stock Titan
ImageneBio Announces Leadership Transition in Finance Organization - The Globe and Mail
ImageneBio Approves Inducement Grants for New Employees Under Nasdaq Rule 5635(c)(4) - geneonline.com
ImageneBio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Bitget
ImageneBio, Inc. Announces Principal Accounting Officer Changes, Effective March 20, 2026 - marketscreener.com
ImageneBio (NASDAQ: IMA) names Bob Lally Principal Accounting Officer as Erin Butler departs - Stock Titan
Two new ImageneBio hires get four-year stock incentive grants - Stock Titan
Atlas Venture Buys Stake in Biotech Firm ImageneBio - National Today
Atlas Venture Life Science Advisors LLC Buys New Position in ImageneBio, Inc. $IMA - Defense World
Wall Street Zen Upgrades ImageneBio (NASDAQ:IMA) to "Hold" - MarketBeat
IMA,CVRX Options - Finviz
Legal and Regulatory Risks: How Litigation and Government Actions Could Impact Imagenebio, Inc.’s Financial Performance - The Globe and Mail
Analysts Are Bullish on Top Healthcare Stocks: Opus Genetics (IRD), ImageneBio (IMA) - The Globe and Mail
ImageneBio, Inc. 2025 10-K: IMG-007 Clinical Development, Strategy, and Market Opportunities in Immunological Diseases - Minichart
ImageneBio, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025 - marketscreener.com
ImageneBio 10-K: License revenue $0.8M; Net loss $45.3M - TradingView
ImageneBio (NASDAQ: IMA) bets on OX40 antibody IMG-007 after Ikena merger - Stock Titan
ImageneBio Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Company Update - The Manila Times
ImageneBio eczema antibody tested in 150+ people without malignancies to date - Stock Titan
Blue Owl Capital Holdings LP Purchases New Stake in ImageneBio, Inc. $IMA - MarketBeat
ImageneBio Inc expected to post a loss of $1.45 a shareEarnings Preview - TradingView
IMA Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
IMA,CVRX Revenue Breakdown - Finviz
ImageneBio to Participate in Leerink Global Healthcare Conference - Eagle-Tribune
BML Capital Management LLC Makes New Investment in ImageneBio, Inc. $IMA - Defense World
ImageneBio (NASDAQ:IMA) Shares Up 2.4% – Still a Buy? - Defense World
ImageneBio announces immediate resignation of board director - TipRanks
ImageneBio (NASDAQ: IMA) prospectus supplement updates resale of 2.5M shares - Stock Titan
ImageneBio, Inc. Announces Resignation of Steven Hui Wang as Member of the Board of Directors, Effective on February 12, 2026 - marketscreener.com
ImageneBio appoints Dr. Porter-Brown as Chief Medical Officer By Investing.com - Investing.com Nigeria
ImageneBio appoints Dr. Porter-Brown as Chief Medical Officer - Investing.com South Africa
ImageneBio Appoints Immunology Drug Development Veteran Dr. Ben Porter-Brown as Chief Medical Officer - marketscreener.com
New ImageneBio CMO to lead late-stage eczema trial using OX40 drug - Stock Titan
ImageneBio Debuts on Nasdaq Following Merger Completion - AD HOC NEWS
ImageneBio (NASDAQ:IMA) Trading Up 0.5%Should You Buy? - MarketBeat
ImageneBio, Inc. (NASDAQ:IMA) Given Consensus Recommendation of "Hold" by Brokerages - MarketBeat
Joseph Slattery Spends US$96k On ImageneBio Stock - simplywall.st
ImageneBio Insider Confidence Rewarded, Stock Hits US$76m Market Cap - Yahoo Finance
Top ImageneBio Insider Makes Bold New Move on Company Stock - TipRanks
Joseph Slattery Buys 16,000 Shares of ImageneBio (NASDAQ:IMA) Stock - MarketBeat
ImageneBio chief medical officer resigns, transition planned - MSN
ImageneBio Chief Medical Officer Resigns, Transition Planned - TipRanks
ImageneBio, Inc. Announces Resignation of Yufang Lu as Chief Medical Officer, effective December 31, 2025 - marketscreener.com
Imagenebio Inc (IMA) 財務データ
収益
当期純利益
現金流量
EPS
1.82%
大文字化:
|
ボリューム (24 時間):